Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)

Authors

• Colleen F. Kelley, Grady Health System, Atlanta, GA
• Maribel Acevedo-Quiñones, Centro Ararat, San Juan, Puerto Rico
• Allison L. Agwu, The Johns Hopkins University School of Medicine, Baltimore, MD
• Anchalee Avihingsanon, Chulalongkorn University, Bangkok, Thailand
• Paul Benson, Be Well Medical Center, Berkley, MI
• Jill Blumenthal, University of California San Diego, San Diego, CA
• Cynthia Brinson, Central Texas Clinical Research, Austin, TX
• Carlos Brites, Complexo Hospitalar Universitário Professor Edgard Santos, Salvador, Brazil
• Pedro Cahn, Fundación Huésped, Buenos Aires, Argentina
• Valeria D. Cantos, Emory University – Ponce de Leon Center Clinical Research Site, Atlanta, GA
• Jesse Clark, University of California, Los Angeles, CA
• Meredith Clement, LSU Health Sciences Center - New OrleansFollow
• Cathy Creticos, Howard Brown Health, Chicago, IL
• Gordon Crofoot, Crofoot MD Clinic and Research Center, Houston, TX
• Ricardo S. Diaz, Universidade Federal de São Paulo, São Paulo, Brazil
• Susanne Doblecki-Lewis, University of Miami Miller School of Medicine, Miami, FL
• Jorge A. Gallardo-Cartagena, Universidad Nacional Mayor de San Marcos, Lima, Peru
• Aditya Gaur, St. Jude Children's Research Hospital, Memphis, TN
• Beatriz Grinsztejn, Instituto Nacional de Infectologia Evandro Chagas, Rio de Janeiro, Brazil
• Juan Carlos Hinojosa, Asociación Civil Selva Amazónica, Iquitos, Peru
• Theo Hodge, Washington Health Institute, Washington, DC
• Richard Kaplan, Desmond Tutu Health Foundation, Cape Town, South Africa
• Marcus Lacerda, Fundação de Medicina Tropical Doutor Heitor Vieira Dourado, Manaus, Brazil
• Anthony LaMarca, Therafirst Medical Center, Fort, FL
• Marcelo H. Losso, Hospital General de Agudos José María Ramos Mejía, Buenos Aires, Argentina
• Jose Valdez Madruga, Centro de Referência e Treinamento DST/AIDS-SP, São Paulo, Brazil
• Kenneth H. Mayer, Harvard Medical School, Boston, MA
• Anthony Mills, Mills Clinical Research, West Hollywood, CA
• Karam Mounzer, Philadelphia FIGHT Community Health Centers,Philadelphia, PA
• et al

Document Type

Conference Proceeding

Publication Date

11-8-2024

Publication Title

Journal of the International AIDS Society

Abstract

HIV Glasgow 2024, November 11 - 13, 2024, UK, Glasgow

Volume

27

Issue

Supplement 6

Comments

Abstract O49; See article for full author list.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Recommended Citation

Kelley, Colleen F.; Acevedo-Quiñones, Maribel; Agwu, Allison L.; Avihingsanon, Anchalee; Benson, Paul; Blumenthal, Jill; Brinson, Cynthia; Brites, Carlos; Cahn, Pedro; Cantos, Valeria D.; Clark, Jesse; Clement, Meredith; Creticos, Cathy; Crofoot, Gordon; Diaz, Ricardo S.; Doblecki-Lewis, Susanne; Gallardo-Cartagena, Jorge A.; Gaur, Aditya; Grinsztejn, Beatriz; Hinojosa, Juan Carlos; Hodge, Theo; Kaplan, Richard; Lacerda, Marcus; LaMarca, Anthony; Losso, Marcelo H.; Madruga, Jose Valdez; Mayer, Kenneth H.; Mills, Anthony; Mounzer, Karam; and al, et, "Twice-yearly lenacapavir PrEP in cisgender gay men, transgender women and men, and gender-diverse people (PURPOSE 2)" (2024). School of Medicine Faculty Publications. 5189.
https://digitalscholar.lsuhsc.edu/som_facpubs/5189
10.1002/jia2.26370